Document is current
Any future updates will be listed below
-
Authors
Damrauer, Jeffrey S. https://orcid.org/0000-0001-8148-0285
Beckabir, Wolfgang
Klomp, Jeff
Zhou, Mi https://orcid.org/0000-0001-8144-3468
Plimack, Elizabeth R. https://orcid.org/0000-0002-7618-0744
Galsky, Matthew D. https://orcid.org/0000-0001-7655-9378
Grivas, Petros
Hahn, Noah M.
O’Donnell, Peter H.
Iyer, Gopa https://orcid.org/0000-0002-5093-6099
Quinn, David I. https://orcid.org/0000-0002-1411-0417
Vincent, Benjamin G. https://orcid.org/0000-0002-1762-2282
Quale, Diane Zipursky
Wobker, Sara E.
Hoadley, Katherine A. https://orcid.org/0000-0002-1216-477X
Kim, William Y. https://orcid.org/0000-0001-7922-2156
Milowsky, Matthew I. https://orcid.org/0000-0002-8965-8129
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA241810, P30-CA016086)
Bladder Cancer Advocacy Network
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 3 September 2021
Accepted: 10 October 2022
First Online: 4 November 2022
Competing interests
: Research support to the author’s institution from Caris Life Sciences (E.R.P.). Payment for advisory board involvement from Astellas, BMS, Merck, Pfizer, Roche/Genentech, and Seattle Genetics, employment Abbvie, Stock options Abbvie (D.I.Q.). No other authors have competing interests relating to this study.
